Summary:
In this issue, Ryan and colleagues describe the preclinical development of a pan-RAF:MEK molecular glue with superior efficacy, brain penetrance, and tolerability in xenograft models of Ras/Raf/MAPK pathway–driven tumors.
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.